Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Personalized therapy: prognostic factors in gastrointestinal stromal tumor (GIST).

Literature DB >> 22752549

Personalized therapy: prognostic factors in gastrointestinal stromal tumor (GIST).

Ronald P Dematteo¹.

Abstract

Entities: Chemical Disease Gene Mutation Species

Mesh：

Substances：

Year: 2012 PMID： 22752549 PMCID： PMC3707794 DOI： 10.1007/s11605-012-1944-0

Source DB: PubMed Journal: J Gastrointest Surg ISSN： 1091-255X Impact factor: 3.452

× No keyword cloud information.

19 in total

1. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival.

Authors: R P DeMatteo; J J Lewis; D Leung; S S Mudan; J M Woodruff; M F Brennan
Journal: Ann Surg Date: 2000-01 Impact factor: 12.969

2. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation.

Authors: Cristina R Antonescu; Peter Besmer; Tianhua Guo; Knarik Arkun; Glory Hom; Beata Koryotowski; Margaret A Leversha; Philip D Jeffrey; Diann Desantis; Samuel Singer; Murray F Brennan; Robert G Maki; Ronald P DeMatteo
Journal: Clin Cancer Res Date: 2005-06-01 Impact factor: 12.531

3. Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants.

Authors: Maria Debiec-Rychter; Jan Cools; Herlinde Dumez; Raf Sciot; Michel Stul; Nicole Mentens; Hilde Vranckx; Bartosz Wasag; Hans Prenen; Johannes Roesel; Anne Hagemeijer; Allan Van Oosterom; Peter Marynen
Journal: Gastroenterology Date: 2005-02 Impact factor: 22.682

4. Outcome of metastatic GIST in the era before tyrosine kinase inhibitors.

Authors: Jason S Gold; Sanne M van der Zwan; Mithat Gönen; Robert G Maki; Samuel Singer; Murray F Brennan; Cristina R Antonescu; Ronald P De Matteo
Journal: Ann Surg Oncol Date: 2006-11-02 Impact factor: 5.344

5. Resistance to Tyrosine Kinase Inhibitors in Gastrointestinal Stromal Tumors.

Authors: Ann W Gramza; Christopher L Corless; Michael C Heinrich
Journal: Clin Cancer Res Date: 2009-12-15 Impact factor: 12.531

6. Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST).

Authors: Ronald P Dematteo; Jason S Gold; Lisa Saran; Mithat Gönen; Kui Hin Liau; Robert G Maki; Samuel Singer; Peter Besmer; Murray F Brennan; Cristina R Antonescu
Journal: Cancer Date: 2008-02-01 Impact factor: 6.860

7. A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors.

Authors: Lei L Chen; Jonathan C Trent; Elsie F Wu; Gregory N Fuller; Latha Ramdas; Wei Zhang; Austin K Raymond; Victor G Prieto; Caroline O Oyedeji; Kelly K Hunt; Raphael E Pollock; Barry W Feig; Kimberly J Hayes; Haesun Choi; Homer A Macapinlac; Walter Hittelman; Marco A Velasco; Shreyaskumar Patel; Michael A Burgess; Robert S Benjamin; Marsha L Frazier
Journal: Cancer Res Date: 2004-09-01 Impact factor: 12.701

8. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.

Authors: Charles D Blanke; George D Demetri; Margaret von Mehren; Michael C Heinrich; Burton Eisenberg; Jonathan A Fletcher; Christopher L Corless; Christopher D M Fletcher; Peter J Roberts; Daniela Heinz; Elisabeth Wehre; Zariana Nikolova; Heikki Joensuu
Journal: J Clin Oncol Date: 2008-02-01 Impact factor: 44.544

9. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.

Authors: George D Demetri; Margaret von Mehren; Charles D Blanke; Annick D Van den Abbeele; Burton Eisenberg; Peter J Roberts; Michael C Heinrich; David A Tuveson; Samuel Singer; Milos Janicek; Jonathan A Fletcher; Stuart G Silverman; Sandra L Silberman; Renaud Capdeville; Beate Kiese; Bin Peng; Sasa Dimitrijevic; Brian J Druker; Christopher Corless; Christopher D M Fletcher; Heikki Joensuu
Journal: N Engl J Med Date: 2002-08-15 Impact factor: 91.245

10. Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis.

Authors: Jason S Gold; Mithat Gönen; Antonio Gutiérrez; Javier Martín Broto; Xavier García-del-Muro; Thomas C Smyrk; Robert G Maki; Samuel Singer; Murray F Brennan; Cristina R Antonescu; John H Donohue; Ronald P DeMatteo
Journal: Lancet Oncol Date: 2009-09-28 Impact factor: 41.316

6 in total

Review 1. Primary gastrointestinal stromal tumors: Current advances in diagnostic biomarkers, prognostic factors and management of its duodenal location.

Authors: Yuesi Zhong; Meihai Deng; Bo Liu; Cheng Chen; Mingliang Li; Ruiyun Xu
Journal: Intractable Rare Dis Res Date: 2013-02

2. SWOG study shows significant long-term overall survival for advanced gastrointestinal stromal tumor patients with imatinib treatment.

Authors: Marcel Trautmann; Sebastian Huss; Wolfgang Hartmann; Eva Wardelmann
Journal: Transl Gastroenterol Hepatol Date: 2018-02-08

Review 6. Ki67 is a biological marker of malignant risk of gastrointestinal stromal tumors: A systematic review and meta-analysis.

Authors: Yu Zhou; Wenqing Hu; Ping Chen; Masanobu Abe; Lei Shi; Si-Yuan Tan; Yong Li; Liang Zong
Journal: Medicine (Baltimore) Date: 2017-08 Impact factor: 1.889